Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02984644 · ClinicalTrials.gov registry record · Phase 3
Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin
A Phase 3 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
NCT02984644 is a Phase 3 study that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 30 participants.
The verdict
NCT02984644, a Phase 3 study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
Study Summary
To determine the role of plasma glucagon and insulin in the rise of endogenous glucose production (EGP) following the SGLT2 inhibition.
Interventions
- DRUG Placebo
- DRUG Dapagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-09-06 |
| Est. Completion | 2019-11-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02984644
The ClinicalTrials.gov registry entry for NCT02984644 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02984644 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02984644 about?
NCT02984644 is a clinical study titled "Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin". To determine the role of plasma glucagon and insulin in the rise of endogenous glucose production (EGP) following the SGLT2 inhibition.
What is the current status of trial NCT02984644?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2017-09-06. Estimated completion is 2019-11-16.
What interventions are being tested in trial NCT02984644?
The interventions under investigation include: Placebo (DRUG), Dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT02984644?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.